SyMap Medical, a Suzhou, China-based medical devices company, raised $100M in funding.
The round was led by Primavera Capital and VMS Group, with the participation of existing investors Simiao Equity Investment and Sequoia Capital China.
Led by Dr. Jie Wang and Mr. Kewen Jin, SyMap Medical provides device therapies for the unmet clinical needs of cardiovascular and pulmonary diseases including hypertension, heart failure, arrhythmia, asthma and early-stage lung cancer.
The company intends to use the funds to accelerate global clinical trials for its products, facilitate the next generation of renal mapping/selective RDN systems and products in interventional pulmonary space, and co-develop technologies with renowned inventors, think tanks and incubators in the U.S. and Israel.
SyMap is conducting two pivotal trials in China, the first is the SMART Study (NCT02761811) using the SyMapCath I™ Catheter/SYMPIONEER S1™ RF system for the treatment of uncontrolled hypertension. This system is based on proprietary technology and is able to map renal nerves for selective renal sympathetic denervation and to provide feedback for physicians before, during, and after the procedure. The second is the BATA Study (NCT03765307) which assesses the efficacy and safety of the Elation™ system to treat severe asthma via bronchial radiofrequency ablations. Both studies are executed by leading clinical investigators and are guided by international experts who serve on the company’s Scientific Advisory Boards. Both systems have been granted “Green Channel Device” status by China’s regulatory agency.